Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 8/20 | 0.40 |
| ▸ | EDNRA | P25101 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6293046 | 0.84 | EDNRA (0.44) | EDNRBEDNRALMNAHCRTR2 | |
| SCHEMBL6288912 | 0.77 | EDNRB (0.40) | EDNRBEDNRAGAAMAPK1 | |
| SCHEMBL6293264 | 0.76 | EDNRB (0.39) | EDNRBEDNRALMNAHCRTR2 | |
| SCHEMBL6289632 | 0.75 | EDNRA (0.54) | EDNRBEDNRA | |
| SCHEMBL6293259 | 0.72 | EDNRA (0.44) | EDNRBEDNRAHCRTR2 | |
| SCHEMBL6289659 | 0.72 | EDNRA (0.42) | EDNRBEDNRALMNA | |
| SCHEMBL6292808 | 0.71 | EDNRA (0.67) | EDNRBEDNRA | |
| SCHEMBL6289699 | 0.71 | EDNRA (0.43) | EDNRBEDNRAHCRTR2 | |
| SCHEMBL6288940 | 0.69 | EDNRA (0.41) | EDNRBEDNRALMNA | |
| SCHEMBL6289771 | 0.69 | KEAP1 (0.36) | EDNRBEDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6962923-B2 | Pyrazole compositions | PFIZER INC. (US) | 2005-11-08 | — | — | US | disclosed |
| US-20030232848-A1 | Pyrazole compositions | PFIZER INC. | 2003-12-18 | — | — | US | disclosed |
| US-6573270-B1 | Endothelin receptor antagonists | PFIZER INC. | 2003-06-03 | — | — | US | disclosed |
| EP-1072597-A1 | Pyrazoles and their use as endothelin antagonists | Pfizer Limited (GB) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232848-A1 | Pyrazole compositions | EDNRB, EDNRA, AGTR1 | EDNRB 1/4885EDNRA 2/4885LMNA 2329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.